Precision BioSciences Inc. Stock News

DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference.

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene edi

In the latest trading session, Precision BioSciences (DTIL) closed at $2.09, marking a -0.95% move from the previous day.

US stock futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern aro

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.83% and 23.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

Precision BioSciences (NASDAQ: DTIL ) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Precision BioSciences missed estimated earnings by 10.64%, reporting an EPS of $-0.52 versus … Full story available on Benzinga.com

Precision BioSciences press release (DTIL): FY GAAP EPS of -$0.52 beats by $0.13.Revenue of $115.53M (+375.8% Y/Y) beats by $2.42M.As of December 31, 2021, the company had…

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.83% and 23.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stoc

Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ: IDYA ) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million. • Citi Trends (NASDAQ: CTRN ) is projected to report quarterly earnings at $1.12 per share on revenue of $250.54 million. • Precision BioSciences (NASDAQ: DTIL ) is likely to report quarterly loss at $0.47 per share on revenue of $7.75 million. • SPX FLOW (NYSE: FLOW ) is estimated to report quarterly loss at $0.17 per share on revenue of $10.88 million. • Brickell Biotech (NASDAQ: BBI ) is likely to report quarterly loss at $0.08 per share on revenue of $150.00 thousand. • Imara (NASDAQ: IMRA ) is expected to report earnings for its fourth quarter. • Gamida Cell (NASDAQ: GMDA ) is estimated to report earnings for its fourth quarter. • Syros Pharmaceuticals (NASDAQ: SYRS ) is likely to report quarterly loss at $0.47 per share on revenue of $4.80 million. • Global X Guru Index ETF (NYSE: GURU ) is likely to report quarterly loss at $0.

Precision BioSciences (DTIL) closed at $3.75 in the latest trading session, marking a -1.32% move from the prior day.

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 41.86% and 6.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Precision BioSciences (DTIL) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.